229 results on '"Scheltens, Philip"'
Search Results
2. Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown
3. Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies
4. Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset
5. The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series
6. Prominent Non-Memory Deficits in Alzheimer’s Disease Are Associated with Faster Disease Progression
7. Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review
8. An Operational Definition of ‘Abnormal Cognition’ to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?
9. End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer’s Disease
10. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology
11. Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort
12. Education as Proxy for Cognitive Reserve in a Large Elderly Memory Clinic: ‘Window of Benefit’
13. Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort
14. Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
15. Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study
16. Driving Difficulties Among Patients with Alzheimer’s Disease and Other Neurodegenerative Disorders
17. The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series.
18. Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma
19. Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population
20. Single Subject Classification of Alzheimer’s Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging
21. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer’s Disease
22. Amsterdam Dementia Cohort: Performing Research to Optimize Care
23. Association Between Later Life Lifestyle Factors and Alzheimer’s Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study
24. The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria
25. Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe
26. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes
27. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly
28. Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity
29. Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease
30. The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients
31. A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease
32. How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study.
33. The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus.
34. Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes
35. Dementia and Rapid Mortality: Who is at Risk?
36. Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort
37. Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia
38. Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer’s Disease
39. Low Prevalence of Mixed Dementia in a Cohort of 2,000 Elderly Patients in a Memory Clinic Setting
40. Integrating Biomarkers for Underlying Alzheimer’s Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers
41. Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology
42. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges
43. Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging.
44. Amsterdam Dementia Cohort: Performing Research to Optimize Care.
45. Matrix Metalloproteinases in Alzheimer’s Disease and Concurrent Cerebral Microbleeds
46. Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer’s Disease
47. Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease
48. Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease
49. Tolerability and Safety of Souvenaid in Patients with Mild Alzheimer's Disease: Results of Multi-Center, 24-Week, Open-Label Extension Study
50. More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.